ACC. Institutional Equities. Event Update. Capacity Expansion To Consolidate Presence In Central India ACCUMULATE

Similar documents
Dalmia Bharat Enterprises

EBITDA 6,223 6,511 (4.4) 5, EBITDA

Indian Oil Corporation

The Ramco Cements. Institutional Equities. Event Update BUY

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance

EBITDA 5,076 3, , EBITDA

EBITDA 2,503 2,904 (13.8) 2,722 (8.0) EBITDA

Sanofi India. Institutional Equities. 3QCY18 Result Update. Robust Performance BUY

Institutional Equities

Gillette India. Institutional Equities. 1QFY18 Result Update

Jamna Auto Industries

Colgate-Palmolive (India)

NESCO. Institutional Equities. Event Update. Revenues From Bombay Exhibition Centre May Take A Hit BUY

Power Mech Projects. Institutional Equities. 2QFY19 Result Update BUY. Strong Order Book Drives Robust Execution

Dalmia Bharat Enterprises

ITC. Institutional Equities. 4QFY18 Result Update. Tracking Expectations ACCUMULATE. Sector: FMCG CMP: Rs286 Target Price: Rs290 Upside: 1%

EBITDA 1,548 1,814 (14.7) 1,561 (0.8) EBITDA

Dalmia Bharat Enterprises

Punjab National Bank

Indian Oil Corporation

Nestle India. Institutional Equities. 1QCY18 Result Update. Resurgence Continues BUY. Sector: FMCG CMP: Rs8,981 Target Price: Rs10,700 Upside: 19%

EBITDA 1,585 1,917 (17.3) 1,673 (5.2) EBITDA

Thermax. Institutional Equities. 3QFY18 Result Update. Healthy Execution, But Margins Disappoint SELL

Mangalam Cement. Institutional Equities. 3QFY18 Result Update. Higher Operating costs Hurt Performance BUY

South Indian Bank. Institutional Equities. 4QFY18 Result Update. Asset Quality Pain To Ease Hereafter BUY. 15 May 2018

Bata India. Institutional Equities. 1QFY19 Result Update BUY

Mold-Tek Packaging. Institutional Equities. Conference Update. Promising Growth Outlook BUY

Institutional Equities

Eicher Motors. Institutional Equities. Management Meet Update BUY. Reuters: EICH.NS; Bloomberg: EIM IN

Punjab National Bank

Institutional Equities

Voltas. Institutional Equities. 1QFY19 Result Update. EMPS Shines, UCP Proves Its Mettle Again ACCUMULATE

26 October 2018 Reuters: MRTI.BO; Bloomberg: MSIL IN

Institutional Equities

Power Mech Projects. Institutional Equities. 2QFY18 Result Update BUY. Strong Business Scalability Likely; Retain Buy

Institutional Equities

Institutional Equities

Timken India. Institutional Equities. 4QFY16 Result Update BUY. Margin Expansion Leads To Huge Growth In Profit; Retain Buy

Institutional Equities

Crisil. Institutional Equities. 3QCY17 Result Update ACCUMULATE. Weak SME Rating Revenues & Currency Movement Play Spoilsport

Swaraj Engines. Institutional Equities. 2QFY18 Result Update ACCUMULATE

TVS Motor Company. Institutional Equities. 3QFY19 Result Update SELL

PNB Housing Finance. Institutional Equities. 4QFY18 Result Update BUY. Continued Display of Embedded Scalability. 4 May 2018

2,09,057 1,85,859 2,17, (4.1) NIM

Institutional Equities

Karnataka Bank. Institutional Equities. 4QFY18 Result Update. Plucky Bank And Low Hanging Fruit BUY. 17 May Reuters: KBNK.NS; Bloomberg: KBL IN

Manappuram Finance. Institutional Equities. 3QFY18 Result Update. The Glitter Is Back In Gold Loans BUY. 9 February 2018

Hindustan Unilever. Institutional Equities. 4QFY18 Result Update

Consolidated Sales (Cr) Growth EBITDA (Cr) Margin PAT Margin EPS (Rs) P/E RoE

Bharat Financial Inclusion

Dabur India. Institutional Equities. 4QFY18 Result Update. Growth Volatility Is Still Fairly High ACCUMULATE

Muthoot Finance. Institutional Equities. 3QFY18 Result Update. Funding Cost Decline Combines With Operating Leverage BUY.

Institutional Equities

18,948 15,784 18, NIM

Crompton Greaves. Institutional Equities. 4QFY15 Result Update ACCUMULATE. Overseas Losses Continue; More Business Exits Likely

Hindustan Unilever. Institutional Equities. 1QFY19 Result Update

Institutional Equities

IFB Industries. Institutional Equities. 3QFY18 Result Update. Healthy Revenues, Strong Gross Margin; Retain Buy BUY.

3,746 2,551 3, NIM

Initiating Coverage. Uflex Ltd.

Muthoot Finance. Institutional Equities. 2QFY18 Result Update BUY

9,500 7,914 8, NIM

EBITDA 5,019 4,211 5, EBITDA

Bata India. Institutional Equities. Management Meet Update. On Right Track ACCUMULATE. Sector: Retail CMP: Rs692 Target Price: 696 Upside: 1%

93,707 77,814 90, NIM

Institutional Equities

CARE Ratings. Institutional Equities. 2QFY18 Result Update BUY

Muthoot Finance. Institutional Equities. 1QFY18 Result Update. Gold Loan Business Continues To Glitter BUY. 10 August 2017

Dabur India. Institutional Equities. 1QFY19 Result Update

PNB Housing Finance. Institutional Equities. 2QFY19 Result Update BUY. Relatively Soft Quarter Not Structural In Nature.

Bajaj Electricals. Institutional Equities. 3QFY15 Result Update

Sequent Scientific. Institutional Equities. 1QFY19 Result Update BUY

E&P To Stay Strong; Consumer Segment To Revive

Institutional Equities

Institutional Equities

Institutional Equities

Cement Sector 27 February 2018

Muthoot Finance. Institutional Equities. 1QFY19 Result Update

Swiss Glascoat Equipments

Muthoot Finance. Institutional Equities. 2QFY19 Result Update. Weak quarter not structural in any way BUY. 10 December 2018

Punjab National Bank

Punjab National Bank

Atul Auto. Institutional Equities. Management Meet Update ACCUMULATE. Sector: Automobile CMP: Rs445 Target Price: Rs489 Upside: 10% 23 August 2017

Manappuram Finance. Institutional Equities. 3QFY17 Result Update BUY

9,251 7,812 8, NIM

La Opala RG. Institutional Equities. 4QFY17 Result Update UNDER REVIEW. Revenues Soar, But Margins Take A Hit. Sector: Tableware CMP: Rs536

Punjab National Bank

Federal Bank. Institutional Equities. Management Meet Update

State Bank of India. Institutional Equities. 3QFY19 Result Update BUY

9,807 8,007 9, NIM

Cadila Healthcare. Institutional Equities. 3QFY15 Result Update UNDER REVIEW. Stable Performance. Sector: Pharmaceuticals CMP: Rs1,514

Hindustan Unilever. Institutional Equities. 3QFY18 Result Update BUY

Institutional Equities

State Bank of India. Institutional Equities. 1QFY18 Result Update

South Indian Bank. Institutional Equities. 1QFY19 Result Update. Performance Troughs, Pessimism Peaks BUY. 23 July 2018

Hindustan Unilever. Institutional Equities. 2QFY19 Result Update

Institutional Equities

Robust results, TLT margins improved profitability.

Sun Pharmaceutical Industries

Operating expenses tracked lower than core total income growth as ABL displayed continued

Transcription:

Event Update Institutional Equities ACC 19 December 218 Reuters: ACC.BO; Bloomberg: ACC IN Capacity Expansion To Consolidate Presence In Central India ACC has announced 5.9mt capacity expansion by adding a greenfield unit near its existing capacity in Kymore, Madhya Pradesh, in central India. Additionally, the company announced expansion of its grinding unit at Sindri (Jharkhand) in the eastern region. This is in line with the recent indications by the parent company, Lafarge Holcim, of further commitment towards its Indian operations. The new 3mt clinker capacity along with 1mt cement grinding unit at Kymore (close to its existing capacity) will be supported by two split grinding units in Uttar Pradesh or UP (expansion at Tikaria by 1.6mt) and a new 2.2mt grinding unit in UP (location yet to be finalised). This is apart from the 1.1mt Sindri grinding unit expansion. The internally funded capital expenditure of Rs3bn (current balance sheet cash of ~ Rs27bn) augurs well as the expansion will be without any balance sheet leverage. The new capacity is likely to be completed in three years, indicating staggered completion of the project. The expanded capacity will be commissioned post CY2 and is internally funded. Our CY18, CY19 and CY2 earnings estimates therefore remain unchanged. The new expansion will allow ACC to tap incremental demand in the Central India and its increased presence in remunerative markets will help average realisation growth post CY2. We have retained Accumulate rating on ACC with an unchanged target price of Rs1,517. Well poised for remunerative markets: The new capacities will be largely added in the remunerative central India region (YTD prices here are 3% higher than the all India average, as per our channel checks). The capacity addition has been slow in this region with a CAGR of ~ 3.5% over FY15-FY2E. This has kept the pricing relatively better as compared with other regions. If a similar trend continues, ACC will increase its presence (24% of total capacity from 14% currently) in the remunerative region post CY21 which will help strengthen its earnings. Clinker conversion ratio maintained without additional stress: Following capacity addition in central and eastern regions, ACC will maintain clinker conversion ratio at a manageable level of 1.4x and 1.5x, respectively. The eastern region is largely a slag cement market and hence higher blending is justified. Though the trend is moving towards the OPC market of late, ACC will still be reasonably poised to cater to the market witnessing incremental OPC/PPC cement demand. Expansion of grinding unit in eastern region to help tap additional demand: The 1.1mt grinding unit expansion at Sindri in Jharkhand will help ACC to tap the eastern region market with focus on Bihar, Jharkhand, West Bengal and the far east. These markets are growing at a healthy pace (double digits) and ACC will be able to add to its volume following the capacity expansion. The clinker for the same will be sourced from Chaibasa (Jharkhand) and other eastern region units. Capacity addition without any balance sheet stress: The capacity addition of 5.9mt will be funded through internal accruals and we foresee no stress on ACC s balance sheet. ACC s current cash of ~Rs27bn and even if no growth is assigned to the cash generated in next two years, we feel the capacity addition can be funded without any stress on the balance sheet. Earnings estimates and rating: The new capacities are expected to be commissioned over the next three years. Hence, at the earliest (assuming capacities are added in a staggered manner), the new capacities will impact earnings post CY2. We have maintained our CY18/CY19/CY2 EPS estimates at Rs54.7/Rs64.4/Rs74., respectively. We expect volume growth to be restricted (current YTD capacity utilisation at 84%) and the performance will be largely driven by realisation gain (despite the disappointment in 3QCY18). Additionally, premium product contribution and a pan-india presence will drive ACC s performance. We have valued ACC at Rs7.5bn/mt based on replacement costs (currently trades at 7.4bn/mt) to arrive at a target price of Rs1,517 (unchanged) based on its September 22 estimated capacity. We have retained Accumulate rating on the stock. ACCUMULATE Sector: Cement CMP: Rs1,51 Target Price: Rs1,517 Upside: 1% Milind Raginwar Research Analyst milind.raginwar@nirmalbang.com +91-22-6273 8172 Key Data Current Shares O/S (mn) 187.8 Mkt Cap (Rsbn/US$bn) 294.3/4.2 52 Wk H / L (Rs) 1,857/1,255 Daily Vol. (3M NSE Avg.) 742,681 Price Performance (%) 1 M 6 M 1 Yr ACC 4.4 22. (9.4) Nifty Index 1.9 2.4 4.9 Source: Bloomberg Y/E December (Rs.mn) CY16 CY17 CY18E CY19E CY2E Net sales 19,364 129,31 139,18 15,727 165,519 EBITDA margin (%) 12.2 13.8 14.5 15.4 15.4 Adjusted net profit 6,452 8,312 1,275 12,12 13,98 versus consensus EPS (Rs) 34.3 44.2 54.7 64.4 74. growth (%) (13.4) 28.8 23.6 17.8 14.9 P/E (x) 43.8 34. 27.5 23.3 2.3 P/B (x) 3.3 3. 2.8 2.6 2.4 EV/EBITDA (x) 19.2 14. 12.4 1.6 9.4 D/E (x) (.3) (.3) (.3) (.3) (.3) RoE (%) 7.6 9.3 11. 12. 12.8 RoCE (%) 1.2 13.7 15.6 16.8 17.2 Dividend yield (%) 1.1 1.1 1.2 1.2 1.2

Exhibit 1: Capacity addition has been followed by volume growth in the past (Mn/T) 35 Capacity Vs Production 3 25 2 15 1 5 CY9 CY1 CY11 CY12 CY13 CY14 CY15 CY16 CY17 CY18E CY19E CY2E Cement capacity (MnT) Cement produced (MnT) Exhibit 2: Lucrative central India region to contribute more in ACC s volume share post expansion, boosting revenues Capacity accross regions before proposed expansion Capacity accross regions post proposed expansion 14% 18% 24% 15% 12% 1% 26% 25% 31% 25% NORTH SOUTH EAST WEST CENTRAL NORTH SOUTH EAST WEST CENTRAL Exhibit 3: ACC s sizeable capacity addition of ~6mt comes after nearly a decade 6 New capacity addition 5 4 3 2 1 CY1 CY12 CY14 CY16 CY18E CY2E Exhibit 4: New capacity announcement Location Grinding unit (mtpa) Capacity added Clinker capacity (mtpa) Ametha, Kymore, Madhya Pradesh 1. 3. Tikaria (Uttar Pradesh) 1.6 - Sindri (Jharkhand) 1.1 - New grinding unit in UP ( location not disclosed) 2.2 - Total 5.9 3. 2 ACC

Oct-6 Mar-7 Aug-7 Jan-8 Jun-8 Nov-8 Apr-9 Sep-9 Feb-1 Jul-1 Dec-1 May-11 Oct-11 Mar-12 Aug-12 Jan-13 Jul-13 Dec-13 May-14 Oct-14 Mar-15 Aug-15 Jan-16 Jun-16 Nov-16 Apr-17 Sep-17 Feb-18 Jul-18 Dec-18 Oct-8 Mar-9 Aug-9 Jan-1 Jun-1 Nov-1 May-11 Oct-11 Mar-12 Aug-12 Jan-13 Jun-13 Nov-13 Apr-14 Sep-14 Feb-15 Jul-15 Dec-15 May-16 Oct-16 Mar-17 Aug-17 Jan-18 Jul-18 Dec-18 Institutional Equities Exhibit 5: One-year forward EV/EBITDA (Rs) 2,4 1,8 1,2 6 Price 8 12 14 16 Exhibit 6: One-year forward EV/tn (Rs) 3, 2,4 1,8 1,2 6 Price $85 $11 $135 $16 $185 3 ACC

Financials Exhibit 7: Income statement Y/E December (Rsmn) CY16 CY17 CY18E CY19E CY2E Net sales 19,364 129,31 139,18 15,727 165,519 Growth (%) (4.3) 18.2 7.6 8.3 9.8 Operating expenses (97,413) (114,97) (121,37) (13,18) (142,555) EBITDA 13,511 18,249 2,598 23,614 25,974 Growth (%) (.1) 35.1 12.9 14.6 1. Depreciation & amortisation (6,52) (6,41) (6,147) (6,541) (6,916) EBIT 9,246 13,164 16,16 18,499 2,554 Other income 1,786 1,317 1,565 1,426 1,496 Interest paid (729) (1,23) (95) (72) (686) Extraordinary/\except. items PBT 8,89 12,983 15,111 17,797 19,868 Tax (2,65) (3,829) (4,835) (5,695) (5,96) Effective tax rate (%) (25.5) (29.5) (32.) (32.) (3.) Net profit 6,24 9,154 1,275 12,12 13,98 Minority interest - - - - - Reported net profit 6,24 9,154 1,275 12,12 13,98 Non-recurring items (428) 842 - - - Adjusted net profit 6,452 8,312 1,275 12,12 13,98 Growth (%) (13.4) 28.8 23.6 17.8 14.9 Exhibit 9: Balance sheet Y/E December (Rsmn) CY16 CY17 CY18E CY19E CY2E Cash & bank balances 2,756 9,785 4,222 2,649 3,259 Other current assets 52,85 61,644 71,465 83,612 94,657 Investments 2,32 2,32 2,32 2,32 2,32 Net fixed assets 76,66 74,566 81,167 82,14 84,829 Goodwill & intangible assets 626 462 226 326 426 Other non-current assets - - - - - Total assets 134,375 148,757 159,382 17,93 185,473 Current liabilities 41,679 49,229 53,468 56,617 6,934 Borrowings 5 592 525 75 1,5 Other non-current liabilities 5,581 5,414 5,414 5,414 5,414 Total liabilities 47,76 55,234 59,47 62,78 67,398 Share capital 1,88 1,88 1,88 1,88 1,88 Reserves & surplus 84,734 91,775 98,96 16,242 116,195 Shareholders' funds 86,614 93,523 99,976 18,122 118,75 Minority interest - - - - - Total equity & liabilities 134,375 148,757 159,382 17,93 185,473 Exhibit 8: Cash flow Y/E December (Rsmn) CY16 CY17 CY18E CY19E CY2E Pre-tax profit 8,89 12,983 15,111 17,797 19,868 Depreciation 5,46 (53,692) 4,541 5,283 5,585 Chg. in working capital 3,17 (4,546) (1,354) (2,744) (486) Total tax paid (1,536) (3,55) (4,62) (5,449) (5,73) Other operating activities - - - - - Operating CF 15,66 (48,759) 13,696 14,887 19,265 Capital expenditure (6,79) 55,896 (1,97) (6,23) (8,5) Chg. in investments (3,456) 3,42 (6,) (6,5) (6,5) Other investment activities - - - - - Investing CF (9,535) 59,298 (16,97) (12,73) (15,) FCF 5,531 1,539 (3,211) 2,157 4,265 Equity raised/(repaid) 6 (133) - - - Debt raised/(repaid) 145 92 (67) 225 3 Dividend (incl. tax) (3,842) (5,198) (2,417) (3,955) (3,955) Other financing activities - 1,73 132 - - Financing CF (3,691) (3,51) (2,352) (3,73) (3,655) Net chg. in cash & bank bal. 1,84 7,29 (5,563) (1,573) 61 Closing cash & bank bal. 2,756 9,785 4,222 2,649 3,259 Exhibit 1: Key ratios Y/E December CY16 CY17 CY18E CY19E CY2E Profitability and return ratios (%) EBITDAM 12.2 13.8 14.5 15.4 15.4 EBITM 8.3 9.9 11.3 12. 12.2 NPM 5.9 6.4 7.4 8. 8.4 RoE 7.6 9.3 11. 12. 12.8 RoCE 1.2 13.7 15.6 16.8 17.2 RoIC 1.1 13.5 14.9 16.1 17.7 Per share data (Rs) O/s shares 187.9 187.9 187.9 187.9 187.9 EPS 34.3 44.2 54.7 64.4 74. FDEPS 34.3 44.2 54.7 64.4 74. CEPS 66.5 78.3 87.4 99.2 11.8 BV 46.7 497.5 531.8 575.1 628.1 DPS 17. 17. 18. 18. 18. Valuation ratios (x) P/E 43.8 34. 27.5 23.3 2.3 P/BV 3.3 3. 2.8 2.6 2.4 EV/EBITDA 19.2 14. 12.4 1.6 9.4 EV/Sales 2.4 2. 1.8 1.7 1.5 Other key ratios D/E (x) (.3) (.3) (.3) (.3) (.3) DSO (days) 16 19 2 21 22 DuPont analysis - RoE NPM (%) 5.9 6.4 7.4 8. 8.4 Asset turnover (x).8.9.9.9 1. Equity multiplier (x) 1.5 1.6 1.6 1.6 1.6 RoE (%) 7.6 9.3 11. 12. 12.8 4 ACC

Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Nov-18 Dec-18 Institutional Equities Rating track Date Rating Market price (Rs) Target price (Rs) 26 March 218 Accumulate 1,549 1,582 2 April 218 Accumulate 1,574 1,612 6 July 218 Accumulate 1,39 1,488 24 July 218 Accumulate 1,473 1,468 19 October 218 Accumulate 1,431 1,517 19 December 218 Accumulate 1,51 1,517 Rating track graph 2, 1,9 1,8 1,7 1,6 1,5 1,4 1,3 1,2 Not Covered Covered 5 ACC

DISCLOSURES This Report is published by Nirmal Bang Equities Private Limited (hereinafter referred to as NBEPL ) for private circulation. NBEPL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 214 having Registration no. INH1436. NBEPL is also a registered Stock Broker with National Stock Exchange of India Limited and BSE Limited in cash and derivatives segments. NBEPL has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets. NBEPL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. NBEPL, its associates or analyst or his relatives do not hold any financial interest in the subject company. NBEPL or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. NBEPL or its associates or Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report. NBEPL or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. NBEPL or its associates have not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of Subject Company and NBEPL / analyst has not been engaged in market making activity of the subject company. Analyst Certification: Mr. Milind Raginwar, the Research Analyst is the author of this report, hereby certify that the views expressed in this research report accurately reflects my/our personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst(s) principally responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations. 6 ACC

Disclaimer Stock Ratings Absolute Returns BUY > 15% ACCUMULATE -5% to15% SELL < -5% This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. NBEPL is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader. This research has been prepared for the general use of the clients of NBEPL and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NBEPL will not treat recipients as customers by virtue of their receiving this report. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NBEPL & its group companies to registration or licensing requirements within such jurisdictions. The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. NBEPL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NBEPL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. This information is subject to change without any prior notice. NBEPL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, NBEPL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries. Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of NBEPL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Here it may be noted that neither NBEPL, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in this report. Copyright of this document vests exclusively with NBEPL. Our reports are also available on our website www.nirmalbang.com Access all our reports on Bloomberg, Thomson Reuters and Factset. Team Details: Name Email Id Direct Line Rahul Arora CEO rahul.arora@nirmalbang.com - Girish Pai Head of Research girish.pai@nirmalbang.com +91 22 6273 817 / 18 Dealing Ravi Jagtiani Dealing Desk ravi.jagtiani@nirmalbang.com +91 22 6273 823, +91 22 6636 8833 Pradeep Kasat Dealing Desk pradeep.kasat@nirmalbang.com +91 22 6273 81/811, +91 22 6636 8831 Michael Pillai Dealing Desk michael.pillai@nirmalbang.com +91 22 6273 812/813, +91 22 6636 883 Nirmal Bang Equities Pvt. Ltd. Correspondence Address B-2, 31/32, Marathon Innova, Nr. Peninsula Corporate Park, Lower Parel (W), Mumbai-413. Board No. : 91 22 6273 8/1; Fax. : 22 6273 81 7 ACC